A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

NCT05236517 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: Semaglutide D Dose 1
DRUG: Semaglutide D Dose 2
DRUG: Semaglutide D Dose 3
DRUG: Semaglutide C Dose 4
DRUG: Semaglutide C Dose 5 (50 mg)
DRUG: Placebo (Semaglutide C)
DRUG: Placebo ( Semaglutide D)

Sponsor

Novo Nordisk A/S